Phytostenone Transdermal Absorbent for Subcutaneous Fat Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively reducing subcutaneous fat, with few materials capable of inhibiting fat absorption, suppressing fat accumulation, or promoting fat metabolism, particularly from a cosmetic and health perspective.
Innovation Solution
A transdermal absorbent product containing phytostenone is applied to the skin, which reduces subcutaneous fat by enhancing fat metabolism and excretion, offering a novel approach to fat reduction that is both therapeutic and cosmetic.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of phytostenone is used to reduce subcutaneous fat, then fat metabolism is accelerated and lipids are excreted, but the treatment time is long and high doses are required
Solution Approach 1:
The patent uses a transdermal delivery system as an intermediary to deliver phytostenone directly to the subcutaneous tissue. This mediator bypasses the digestive system and first-pass metabolism, enabling direct local action of phytostenone on subcutaneous fat with faster onset and reduced treatment time compared to oral administration
Solution Approach 2:
The patent changes the administration route from oral to transdermal, which fundamentally alters the pharmacokinetic parameters including absorption rate, bioavailability, and local concentration. This parameter change enables achieving the same fat reduction effect with lower total doses and shorter treatment duration
2Reliability
If oral administration of phytostenone is used to reduce subcutaneous fat, then fat metabolism is promoted, but the dose required is high
Solution Approach 1:
The patent applies phytostenone locally to the skin area overlying the subcutaneous fat deposits. This local application creates a high concentration gradient at the target site, enabling effective fat metabolism promotion with much lower total doses compared to oral administration that distributes the substance systemically
Solution Approach 2:
The transdermal delivery system acts as an intermediary that concentrates phytostenone directly at the subcutaneous tissue interface, improving local bioavailability and reducing the total quantity of phytostenone needed to achieve therapeutic effect
3Reliability
If conventional fat reduction materials are used, then some fat metabolism effect is achieved, but subcutaneous fat reduction is insufficient
Solution Approach 1:
The patent targets specifically subcutaneous fat by applying phytostenone topically to the skin area overlying the fat deposits. This localized application provides precise targeting of subcutaneous fat while sparing other fat depots, achieving superior precision compared to conventional systemic treatments that affect all fat tissue non-selectively
Solution Approach 2:
The transdermal delivery system serves as a selective intermediary that delivers phytostenone preferentially to subcutaneous tissue through the skin barrier, enabling precise localization of the therapeutic effect to subcutaneous fat deposits while minimizing effects on visceral and other fat tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal application of phytostenone effectively reduces subcutaneous fat, achieving up to 40% reduction in a shorter time with lower doses compared to oral administration, while preferentially targeting subcutaneous fat over visceral fat, improving both health and beauty outcomes.
Implementation Method 1
a transdermal absorbent product comprising a phytostenone
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
According to the present invention, a transdermal absorbent for reducing a subcutaneous fat is provided, which comprises phytostenone. Accordingly, a method for further reducing a subcutaneous fat can be provided.